Fluctuating numbers of circulating tumor cells in cancer patients and the meaning of zero counts
Fluctuating numbers of circulating tumor cells in cancer patients and the meaning of zero counts |
|
https://doi.org/10.18632/oncotarget.26850
Nicola Aceto
|
| 2658-2659 |
Chromosomes missegregated into micronuclei contribute to chromosomal instability by missegregating at the next division
Chromosomes missegregated into micronuclei contribute to chromosomal instability by missegregating at the next division |
|
https://doi.org/10.18632/oncotarget.26853
Bin He,
Nisha Gnawali,
Albert W. Hinman,
Aaron J. Mattingly,
Alyssa Osimani,
and Daniela Cimini
|
| 2660-2674 |
Characterization of cancer-associated IDH2 mutations that differ in tumorigenicity, chemosensitivity and 2-hydroxyglutarate production
Characterization of cancer-associated IDH2 mutations that differ in tumorigenicity, chemosensitivity and 2-hydroxyglutarate production |
|
https://doi.org/10.18632/oncotarget.26848
Kevin P. Kotredes,
Roshanak Razmpour,
Evan Lutton,
Mercedes Alfonso-Prieto,
Servio H. Ramirez,
and Ana M. Gamero
|
| 2675-2692 |
Genomic landscape analyses of reprogrammed cells using integrative and non-integrative methods reveal variable cancer-associated alterations
Genomic landscape analyses of reprogrammed cells using integrative and non-integrative methods reveal variable cancer-associated alterations |
|
https://doi.org/10.18632/oncotarget.26857
Frank Griscelli,
Christophe Desterke,
Olivier Feraud,
Dominique Divers,
Noufissa Oudrhiri,
Lucie Tosca,
Ali G. Turhan,
and Annelise Bennaceur-Griscelli
|
| 2693-2708 |
Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts
Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts |
|
https://doi.org/10.18632/oncotarget.26831
Jesus Delgado-Calle,
Noriyoshi Kurihara,
Emily G. Atkinson,
Jessica Nelson,
Kazuaki Miyagawa,
Carlos Maria Galmarini,
G. David Roodman,
and Teresita Bellido
|
| 2709-2721 |
Computational analysis of data from a genome-wide screening identifies new PARP1 functional interactors as potential therapeutic targets
Computational analysis of data from a genome-wide screening identifies new PARP1 functional interactors as potential therapeutic targets |
|
https://doi.org/10.18632/oncotarget.26812
Samuele Lodovichi,
Alberto Mercatanti,
Tiziana Cervelli,
and Alvaro Galli
|
| 2722-2737 |
BCR: a promiscuous fusion partner in hematopoietic disorders
BCR: a promiscuous fusion partner in hematopoietic disorders |
|
https://doi.org/10.18632/oncotarget.26837
Malalage N. Peiris,
Fangda Li,
and Daniel J. Donoghue
|
| 2738-2754 |
MEF-2 isoforms’ (A-D) roles in development and tumorigenesis
MEF-2 isoforms’ (A-D) roles in development and tumorigenesis |
|
https://doi.org/10.18632/oncotarget.26763
Kiran Madugula,
Ria Mulherkar,
Zafar K. Khan,
DeGaulle I. Chigbu,
Dip Patel,
Edward W. Harhaj,
and Pooja Jain
|
| 2755-2787 |
Correction: Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes
Correction: Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes |
|
https://doi.org/10.18632/oncotarget.26881
Tina Huang,
Roxanna Garcia,
Jin Qi,
Rishi Lulla,
Craig Horbinski,
Amir Behdad,
Nitin Wadhwani,
Ali Shilatifard,
Charles James,
and Amanda M. Saratsis
|
| 2788-2788 |
